MDT Stock Price Today (September 2026) — Medtronic plc Analysis & Key Metrics 2026-09-03
Medtronic plc (MDT) is trading at $93.10, up 1.00% today (as of September 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $98.84 (6.2% upside).
- Volatility remains elevated (19.44% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (9.90% YoY) alongside significant competitive pressures.
MDT Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Medtronic plc - Historical Price & Volume
Market Cap
Enterprise Value: $137.32B
P/E Ratio
Forward P/E: 14.15
Revenue Growth
Year over Year
Analyst Target
+6.2% upside potential
Key Investor Questions About MDT
What investors need to know before buying
Based on current market data, MDT presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 61.74)
- Fundamentals say: Caution warranted (high leverage concerns)
MDT's growth trajectory depends on its ability to expand within the Medical Devices sector while managing margin pressures.
- Future growth will depend on performance in core Medical Devices operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for MDT investors include debt exposure and competitive dynamics in the Medical Devices industry.
- $29.15B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Medical Devices.
52-Week Trading Range
Over the past year, MDT stock traded between $73.31 and $106.33—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 19.44% annualized volatility and β=0.41, the stock exhibits low sensitivity to market moves—making MDT suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
4 Reasons to Buy Medtronic Stock Like There's No Tomorrow
The medical device maker is on the cusp of a multi-year recovery.
Is Johnson & Johnson Stock Priced For More Growth Than It Has Guided?
Johnson & Johnson (JNJ) has had a good year. The stock is up 56.5% over the past twelve months against 19.1% for the S&P 500, and at $271.19 sits at about 99% of its 52-week high. The business is still growing. The risk is that the current stock price discounts an acceleration well ahead of management's near-term guidance.
Earnings Calendar and Analysis for This Week (August 31-September 4)
Check out our earnings calendar for this week, as well as our previews and recaps of the more noteworthy reports.
Cyberattack & Weak 2026 Outlook Weigh on BSX: Is the Stock a Sell?
Boston Scientific faces a cyberattack, weaker 2026 guidance and business pressures, raising concerns over its outlook and whether investors should exit.
ISRG Stock: The Best House On The Block Costs The Most
In the world of robotic surgery, one company is both the undisputed leader and the most expensive option, forcing investors to ask if operational excellence is worth the premium.
3 AI Stocks To Watch With Up To 45% Earnings Growth
With central banks lifting interest rates to tackle inflation, investors are hunting for themes that do not rely purely on cheap money to grow. Artificial intelligence in healthcare is one such story. It focuses on software and data rather than heavy assets. This article highlights three Transformative AI Healthcare Stocks from our screener that apply algorithms to diagnostics, treatment decisions, and hospital efficiency. The three stocks that follow are only a starting sample from this...
Should Investors Buy SOLV as Growth Improves but Debt Risks Persist?
Solventum's growth, higher earnings outlook and cost cuts strengthen its case, but heavy debt and 2027 margin risks temper the upside.
The Wide Divide Priced Into Boston Scientific Stock
The market's valuation reflects a wide breadth of potential outcomes for the company, exposing shareholders to the full magnitude of that underlying risk.
Is Medtronic Stock Underperforming the Dow?
While Medtronic has outperformed relative to the Dow over the past three months, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.
Medtronic Begins Fiscal 2027 With a Beat-and-Raise, Validating Growth Acceleration, RBC Says
Medtronic (MDT) delivered a broad-based beat-and-raise to begin fiscal 2027, marking a defining step
Explore More Analysis for MDT
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Medtronic plc
Medtronic plc (MDT) is currently trading at $93.10. The RSI (14-day) is at 61.7, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $98.84 implies 6.2% upside from current levels. Volatility is low at 19.4% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Medtronic plc (MDT): The trailing P/E ratio is 24.96, which is in line with broader market averages. The forward P/E is 14.15, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.78, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 2.41. Price-to-Sales is 3.28. Valuation should be compared to Medical Devices industry peers for context, as different sectors trade at different multiples.
Based on 25 analysts covering MDT, the consensus price target is $98.84. This represents a 6.2% upside from the current price of $93.10. The range spans from a low target of $78.00 to a high target of $121.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Medtronic plc (MDT) pays a dividend with a current yield of approximately 3.09%. The annualized dividend rate is $2.84 per share. The payout ratio is 76.1%, which is relatively high—earnings cover the dividend but there's limited room for increases. The most recent ex-dividend date was 2026-09-25T00:00:00.000Z.
Key risks for Medtronic plc (MDT) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Medical Devices sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Medtronic plc's (MDT) current debt and financial health profile: Total debt stands at $29.15B. The debt-to-equity ratio is 58.21, which is moderate and generally manageable for most companies. The current ratio is 2.13, indicating strong short-term liquidity. The quick ratio is 1.36. The company holds $9.22B in cash and equivalents. Free cash flow is positive at $4.63B, providing a cushion for debt servicing and shareholder returns.